HALB.US Tykhe Corp
- Market cap
- USD 1.20M
- P/E
- -
- P/B
- 16.90x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jan 2026.
Is HALB.US undervalued?
Graham numberThe Graham number of Tykhe Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tykhe Corp fundamental analysis
No fundamental analysis for Tykhe Corp yet.
Tykhe Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tykhe Corp
Halberd Corporation, a biotech company, develops treatments for blood-borne and neurologic diseases. It offers treatments for post-traumatic stress disorder/chronic traumatic encephalopathy, cancer, and COVID-19. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
Full company profileTykhe Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jan 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tykhe Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 164K | 151K | - | - | - | 5.24K | 8.02K | 2.73K | 999.00 | - | - |
| Gross Profit | 164K | 151K | - | - | - | 943.00 | 7.81K | 1.32K | -207.00 | -549.00 | -732.00 |
| Operating Income | 74.8K | -238K | -14.2K | -21.9K | -1.64M | -856K | -1.62M | -447K | -75.1K | -18.7K | -64.4K |
| EBITDA | 75.1K | -307K | -14.2K | -21.9K | 8.09K | 84.7K | -1.62M | -446K | -74.3K | -18.1K | -63.6K |
| Net Income | 5.98K | -373K | -14.2K | -21.9K | -1.64M | -862K | -1.62M | -454K | -79.7K | -20.1K | -70.0K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 599K | 419K | - | - | 4.34K | 63.4K | 17.1K | 12.3K | 10.1K | 4.49K | 4.12K |
| Total Liabilities | 1.23M | 1.04M | - | 470K | 289K | 549K | 745K | 939K | 729K | 918K | 878K |
| Shareholders' Equity | -629K | -622K | - | -470K | -285K | -485K | -728K | -926K | -719K | -913K | -874K |
| Cash & Short-term Investments | 663.00 | 6.00 | - | - | 2.09K | 40.3K | 9.54K | 6.92K | 5.28K | - | - |
| Total Debt | 684K | 460K | - | - | - | 150K | 150K | 150K | 150K | 150K | 150K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -301.00 | -657.00 | -6.00 | -21.9K | -42.6K | -770K | -920K | -241K | -51.6K | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 1.28K | 1.28K | 3.85K | 0.00 | 4.00 | - | - |
| Free Cash Flow | -301.00 | -657.00 | -6.00 | -21.9K | -42.6K | -772K | -924K | -241K | -51.6K | - | - |
| Ratios | |||||||||||
| ROA | 1.0% | -88.9% | - | - | -37,915.1% | -1,359.9% | -9,505.3% | -3,697.4% | -786.5% | -447.4% | -1,698.6% |
| Net Profit Margin | 3.6% | -246.7% | - | - | - | -16,447.8% | -20,258.7% | -16,663.2% | -7,975.6% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tykhe Corp dividends
Tykhe Corp has not paid dividends in the last 10 fiscal years.
Who owns Tykhe Corp
Ownership data of Tykhe Corp is not available yet.
Tykhe Corp company profile
- Company name
- Tykhe Corp
- Ticker
- HALB.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- July
- Address
- PO Box 25, Jackson Center, PA, United States, 16133
- Phone
- 814 786 8849
- Website
- halberdcorporation.com
About Tykhe Corp
Halberd Corporation, a biotech company, develops treatments for blood-borne and neurologic diseases. It offers treatments for post-traumatic stress disorder/chronic traumatic encephalopathy, cancer, and COVID-19. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
Tykhe Corp management
5- Mr. William A. HartmanPresident, CEO & Chairman · born 1942
- Mr. John S. Borza AVS, MBA, PECOO & Director · born 1954
- Ms. Heidi H. CarlDirector & Accounting Director · born 1971
- Dr. Mitchell S. Felder M.D.CTO & Member of the Scientific Advisory Board · born 1954
- Dr. Patricio F. Reyes FAAN, M.D.Chief Mechanical Officer & Member of the Scientific Advisory Board · born 1947